Weekly Recap: 7.00% Series A convertibles and acoramidis renal data

BridgeBio Pharma (NASDAQ:BBIO) raised capital via Series A convertible preferred shares carrying a 7.00% dividend and conversion/redemption mechanics, while clinical updates on acoramidis showed an early reversible eGFR dip, meaningful UACR reductions and a +2.47 mL/min/1.73m²/year eGFR slope improvement.

Previous Week Recap

• BridgeBio Series A Convertible: BridgeBio issued Series A convertible preferred shares: 7.00% annual dividend (cash or PIK), initial conversion price $137.79, step-up to $153.10 after five years, issuer redemption/conversion rights
• Acord In ATTRibute Data: BridgeBio (BBIO) reported acoramidis post‑hoc ATTRibute data: reversible initial eGFR dip, 15.5% placebo‑corrected UACR cut by Day 28, +2.47 mL/min/1.73m²/year eGFR slope, 13.7% UACR drop at Month 30

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.